What will Johnson & Johnson say during their next earnings call? — On Oct 13, 2026
Markets
Every market on this event, moneyline first. Select one to compare it across platforms in the side panel.
| Outcome | Best | Volume | Azuro | Gemini | Kalshi | Limitless | Novig | Polymarket | Polymarket US |
|---|---|---|---|---|---|---|---|---|---|
Ottava Favorite | 98.0%Kalshi | $9.8K | — | — | — | — | — | — | |
Procedure | 96.0%Kalshi | $8.7K | — | — | — | — | — | — | |
Rybrevant | 95.0%Kalshi | $5.5K | — | — | — | — | — | — | |
Tecvayli | 95.0%Kalshi | $6.6K | — | — | — | — | — | — | |
China | 95.0%Kalshi | $3.9K | — | — | — | — | — | — | |
Firefly Bio | 99.0%Kalshi | $1.9K | — | — | — | — | — | — | |
Caplyta | 92.0%Kalshi | $3.9K | — | — | — | — | — | — | |
Tariff | 85.0%Kalshi | $2.6K | — | — | — | — | — | — | |
Litigation | 80.0%Kalshi | $2.5K | — | — | — | — | — | — | |
Darzalex Faspro | 64.0%Kalshi | $363 | — | — | — | — | — | — | |
AI / Artificial Intelligence | 49.0%Kalshi | $3.0K | — | — | — | — | — | — | |
Nipocalimab / Lupus | 41.0%Kalshi | $307 | — | — | — | — | — | — | |
Administration | 37.0%Kalshi | $212 | — | — | — | — | — | — | |
Halda Therapeutics | 35.0%Kalshi | $543 | — | — | — | — | — | — | |
Vaccine | 10.0%Kalshi | $835 | — | — | — | — | — | — | |
Description from Kalshi. A cross-platform summary is generated once this event is matched across platforms.
How this is resolved Video of the Johnson & Johnson earnings call. If a consensus by Kalshi employees cannot be reached using video, transcripts of the Johnson & Johnson earnings call will be used according to the news publications listed in the contract. Payout criteria The exact phrase/word, or a plural or possessive form of the phrase/word. Doesn't count for payout Grammatical/tense inflections. Kalshi is not affiliated, associated, authorized, endorsed by, or in any way officially connected with the underlying company. All trademarks, logos, and brand names are the property of their respective owners.
Discussion (0)
Log in to join the discussion.
No comments yet — start the discussion.